Clinical Trial Update: Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib in castration-resistant prostate cancer was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: University of Washington | Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-01-01